Eduard Vieta1, Trisha Suppes. 1. Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain. evieta@clinic.ub.es
Abstract
OBJECTIVE: As a commitment to the International Society for Bipolar Disorders (ISBD), a Task Force was developed to investigate the diagnostic value of bipolar II disorder. METHODS: Task Force members worked jointly reviewing all relevant literature (original articles, reviews, letters, book chapters and congress presentations) that included 'bipolar II disorder' and/or 'hypomania' as key words. RESULTS: Bipolar II disorder appears to be a reasonably valid and reliable diagnostic category yet often underdiagnosed or misdiagnosed as unipolar disorder or personality disorder. Moreover, it is officially recognized as a mental disorder in DSM-IV-TR but not in ICD-10, and many clinicians still regard it as a milder form of manic-depressive illness, despite data supporting high morbidity and mortality rates. In fact, bipolar II may be the most prevalent bipolar phenotype, although current diagnostic boundaries are seen as quite restrictive concerning the required duration for hypomania (4 days), the exclusion of hypomanic episodes potentially triggered by antidepressants and other substances, and the negligence of hypomanic mixed states. The course of bipolar II disorder is characterized by depressive predominant polarity, and its treatment is still controversial and poorly evidence-based. CONCLUSIONS: Bipolar II disorder is supported as a distinct category within mood disorders, but the definition and boundaries deserve a greater clarification in the DSM-V and ICD-11.
OBJECTIVE: As a commitment to the International Society for Bipolar Disorders (ISBD), a Task Force was developed to investigate the diagnostic value of bipolar II disorder. METHODS: Task Force members worked jointly reviewing all relevant literature (original articles, reviews, letters, book chapters and congress presentations) that included 'bipolar II disorder' and/or 'hypomania' as key words. RESULTS:Bipolar II disorder appears to be a reasonably valid and reliable diagnostic category yet often underdiagnosed or misdiagnosed as unipolar disorder or personality disorder. Moreover, it is officially recognized as a mental disorder in DSM-IV-TR but not in ICD-10, and many clinicians still regard it as a milder form of manic-depressive illness, despite data supporting high morbidity and mortality rates. In fact, bipolar II may be the most prevalent bipolar phenotype, although current diagnostic boundaries are seen as quite restrictive concerning the required duration for hypomania (4 days), the exclusion of hypomanic episodes potentially triggered by antidepressants and other substances, and the negligence of hypomanic mixed states. The course of bipolar II disorder is characterized by depressive predominant polarity, and its treatment is still controversial and poorly evidence-based. CONCLUSIONS:Bipolar II disorder is supported as a distinct category within mood disorders, but the definition and boundaries deserve a greater clarification in the DSM-V and ICD-11.
Authors: Nathalie Vizueta; Jeffrey D Rudie; Jennifer D Townsend; Salvatore Torrisi; Teena D Moody; Susan Y Bookheimer; Lori L Altshuler Journal: Am J Psychiatry Date: 2012-08 Impact factor: 18.112
Authors: J Angst; A Gamma; C L Bowden; J M Azorin; G Perugi; E Vieta; A H Young Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-08-05 Impact factor: 5.270
Authors: Daniel Ong; Mark Walterfang; Gin S Malhi; Martin Styner; Dennis Velakoulis; Christos Pantelis Journal: Aust N Z J Psychiatry Date: 2012-02-24 Impact factor: 5.744
Authors: Boris Birmaher; David Axelson; Benjamin Goldstein; Michael Strober; Mary Kay Gill; Jeffrey Hunt; Patricia Houck; Wonho Ha; Satish Iyengar; Eunice Kim; Shirley Yen; Heather Hower; Christianne Esposito-Smythers; Tina Goldstein; Neal Ryan; Martin Keller Journal: Am J Psychiatry Date: 2009-05-15 Impact factor: 18.112
Authors: Geoffrey M Reed; Michael B First; Cary S Kogan; Steven E Hyman; Oye Gureje; Wolfgang Gaebel; Mario Maj; Dan J Stein; Andreas Maercker; Peter Tyrer; Angelica Claudino; Elena Garralda; Luis Salvador-Carulla; Rajat Ray; John B Saunders; Tarun Dua; Vladimir Poznyak; María Elena Medina-Mora; Kathleen M Pike; José L Ayuso-Mateos; Shigenobu Kanba; Jared W Keeley; Brigitte Khoury; Valery N Krasnov; Maya Kulygina; Anne M Lovell; Jair de Jesus Mari; Toshimasa Maruta; Chihiro Matsumoto; Tahilia J Rebello; Michael C Roberts; Rebeca Robles; Pratap Sharan; Min Zhao; Assen Jablensky; Pichet Udomratn; Afarin Rahimi-Movaghar; Per-Anders Rydelius; Sabine Bährer-Kohler; Ann D Watts; Shekhar Saxena Journal: World Psychiatry Date: 2019-02 Impact factor: 49.548